Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
9.12
-0.14 (-1.51%)
At close: Oct 28, 2025, 4:00 PM EDT
9.12
0.00 (0.00%)
After-hours: Oct 28, 2025, 4:00 PM EDT
Valneva SE Revenue
Valneva SE had revenue of 48.33M EUR in the quarter ending June 30, 2025, with 26.98% growth. This brings the company's revenue in the last twelve months to 196.33M, up 25.47% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
196.33M EUR
Revenue Growth
+25.47%
P/S Ratio
3.39
Revenue / Employee
275,353 EUR
Employees
713
Market Cap
780.96M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
VALN News
- 1 day ago - Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences - GlobeNewsWire
- 22 days ago - Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates - GlobeNewsWire
- 4 weeks ago - Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 7 weeks ago - Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate - GlobeNewsWire
- 2 months ago - Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday - Benzinga
- 2 months ago - Johnson Fistel Investigates Valneva Following FDA Suspension - GlobeNewsWire
- 2 months ago - Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US - Benzinga
- 2 months ago - FDA suspends Valneva's chikungunya vaccine license in the U.S. - Reuters